Related party transactions

6 Months Ended

Jun. 30, 2024

Related party transactions

Related party transactions

12. Related-party transactions

During the three and six months ended June 30, 2024, the Company received scientific advisory board and other scientific advisory services from Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Sah for services provided during the three and six months ended June 30, 2024, was $150,000 and $300,000, respectively. The total amount of fees paid to Dr. Sah for services provided during the three and six months ended June 30, 2023 was $184,000 and $383,800, respectively. During the second quarter of 2023, the Company and Dr. Sah agreed to a fee of $50,000 per month for advisory services from Dr. Sah pursuant to an amendment to the Company’s consulting agreement with Dr. Sah that became effective in June 2023.

Under each of the Company’s collaboration agreements with Neurocrine, the Company and Neurocrine have agreed to conduct research, development, and commercialization activities for certain of the Company’s AAV gene therapy product candidates. Amounts due from Neurocrine are reflected as related party collaboration receivables. As of June 30, 2024, the Company had approximately $0.9 million in related party collaboration receivables associated with the 2023 Neurocrine Collaboration Agreement and approximately $0.7 million in related party collaboration receivables associated with the 2019 Neurocrine Collaboration Agreement.